Outcomes of intravenous and inhalation anesthesia on patients undergoing esophageal cancer surgery: a retrospective observational study.
Disease-free survival
Esophageal cancer
INHA
Overall survival
TIVA
Journal
BMC anesthesiology
ISSN: 1471-2253
Titre abrégé: BMC Anesthesiol
Pays: England
ID NLM: 100968535
Informations de publication
Date de publication:
02 03 2023
02 03 2023
Historique:
received:
18
12
2022
accepted:
17
02
2023
entrez:
2
3
2023
pubmed:
3
3
2023
medline:
7
3
2023
Statut:
epublish
Résumé
Different anesthetics may have opposite effects on the immune system, thus affecting the prognosis of tumor patients. Cell-mediated immunity forms the primary defense against the invasion of tumor cells, so manipulation of the immune system to produce an enhanced anti-tumor response could be utilized as an adjuvant oncological therapy. Sevoflurane has proinflammatory effects, while propofol, has anti-inflammatory and antioxidant effects. Therefore, we compared the overall survival (OS) and disease-free survival (DFS) of patients with esophageal cancer under total intravenous anesthesia and inhalation anesthesia. This study collected the electronic medical records of patients undergoing esophagectomy from January 1, 2014 to December 31, 2016. According to the intraoperative anesthetics, the patients were divided into total intravenous anesthesia (TIVA) group or inhalational anesthesia (INHA) group. Stabilized inverse probability of treatment weighting (SIPTW) was used to minimize differences. Kaplan-Meier survival curve was established to evaluate the correlation between different anesthesia methods in overall survival and disease-free survival of patients undergoing esophageal cancer surgery. A total of 420 patients with elective esophageal cancer were collected, including 363 patients eligible for study (TIVA, n = 147, INHA, n = 216). After SIPTW there were no significant differences between two groups in overall survival and disease-free survival. However, the adjuvant therapy was statistically significant in improving OS, and the degree of differentiation was correlated with OS and DFS. In conclusion, there were no significant difference in overall survival and disease-free survival between total intravenous anesthesia and inhalational anesthesia in patients undergoing esophageal cancer surgery.
Sections du résumé
BACKGROUND
Different anesthetics may have opposite effects on the immune system, thus affecting the prognosis of tumor patients. Cell-mediated immunity forms the primary defense against the invasion of tumor cells, so manipulation of the immune system to produce an enhanced anti-tumor response could be utilized as an adjuvant oncological therapy. Sevoflurane has proinflammatory effects, while propofol, has anti-inflammatory and antioxidant effects. Therefore, we compared the overall survival (OS) and disease-free survival (DFS) of patients with esophageal cancer under total intravenous anesthesia and inhalation anesthesia.
METHODS
This study collected the electronic medical records of patients undergoing esophagectomy from January 1, 2014 to December 31, 2016. According to the intraoperative anesthetics, the patients were divided into total intravenous anesthesia (TIVA) group or inhalational anesthesia (INHA) group. Stabilized inverse probability of treatment weighting (SIPTW) was used to minimize differences. Kaplan-Meier survival curve was established to evaluate the correlation between different anesthesia methods in overall survival and disease-free survival of patients undergoing esophageal cancer surgery.
RESULTS
A total of 420 patients with elective esophageal cancer were collected, including 363 patients eligible for study (TIVA, n = 147, INHA, n = 216). After SIPTW there were no significant differences between two groups in overall survival and disease-free survival. However, the adjuvant therapy was statistically significant in improving OS, and the degree of differentiation was correlated with OS and DFS.
CONCLUSIONS
In conclusion, there were no significant difference in overall survival and disease-free survival between total intravenous anesthesia and inhalational anesthesia in patients undergoing esophageal cancer surgery.
Identifiants
pubmed: 36864402
doi: 10.1186/s12871-023-02023-1
pii: 10.1186/s12871-023-02023-1
pmc: PMC9979524
doi:
Substances chimiques
Anesthetics, Inhalation
0
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
66Subventions
Organisme : Postdoctoral Foundation of Hei Long Jiang Province
ID : LBH-Q20134
Organisme : Postdoctoral Foundation of Hei Long Jiang Province
ID : LBH-Q21115
Organisme : China GuangHua Science and Technology Foundation
ID : 2022-33
Informations de copyright
© 2023. The Author(s).
Références
Can J Anaesth. 2019 May;66(5):546-561
pubmed: 30834506
J Oncol. 2021 Feb 17;2021:6675691
pubmed: 33679976
World J Gastroenterol. 2019 Dec 21;25(47):6835-6846
pubmed: 31885424
J Healthc Eng. 2022 Mar 12;2022:4752609
pubmed: 35313517
Anesth Pain Med. 2022 Feb 22;12(1):e123463
pubmed: 35433388
J Thorac Dis. 2021 Oct;13(10):6037-6051
pubmed: 34795950
Anesthesiology. 2020 Oct 1;133(4):764-773
pubmed: 32930730
J Clin Med. 2018 Feb 19;7(2):
pubmed: 29463006
Acta Anaesthesiol Scand. 2019 Oct;63(9):1169-1177
pubmed: 31180151
Value Health. 2010 Mar-Apr;13(2):273-7
pubmed: 19912596
Int J Physiol Pathophysiol Pharmacol. 2019 Jun 25;11(3):83-94
pubmed: 31333811
J BUON. 2019 May-Jun;24(3):1240-1244
pubmed: 31424685
Eur J Cancer. 2018 May;94:138-147
pubmed: 29571082
BMC Anesthesiol. 2017 Dec 4;17(1):164
pubmed: 29202701
BMC Cancer. 2018 Feb 7;18(1):159
pubmed: 29415668
BMC Anesthesiol. 2022 May 30;22(1):169
pubmed: 35637441
Sci Rep. 2017 Oct 25;7(1):14020
pubmed: 29070852
Int J Surg. 2018 Jul;55:24-30
pubmed: 29578096
BMC Anesthesiol. 2022 Jul 25;22(1):236
pubmed: 35879661
Ann Surg. 2022 Jul 15;:
pubmed: 35837948
Am J Transl Res. 2021 Oct 15;13(10):11427-11438
pubmed: 34786069
J Clin Anesth. 2017 Nov;42:19-25
pubmed: 28797751